



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/825,922	04/05/2001	David E. Comings	1954-332	3812

6449 7590 03/25/2003

ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
1425 K STREET, N.W.  
SUITE 800  
WASHINGTON, DC 20005

EXAMINER

GOLDBERG, JEANINE ANNE

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 03/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

## Application No.

09/825,922

## Applicant(s)

COMINGS, DAVID E.

## Examiner

Jeanine A Goldberg

## Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 23 December 2002.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 55-64 is/are pending in the application.
- 4a) Of the above claim(s) 55-59, 63 and 64 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 60-62 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

### **DETAILED ACTION**

1. This action is in response to the papers filed December 23, 2002. Currently, claims 55-64 are pending. All arguments have been thoroughly reviewed but are deemed non-persuasive for the reasons which follow. This action is made FINAL.
2. Any objections and rejections not reiterated below are hereby withdrawn.
3. This action contains new grounds of rejection necessitated by amendment.

### ***Maintained Rejections***

### ***Election/Restrictions***

4. Applicant's election with traverse of Group I, Claims 1-15 in Paper No. 11 is acknowledged. Applicant's do not traverse the restriction between the various groups. However, Applicant's traverse the restriction to a single gene. The response asserts that Claims 2 and 3 are directed to combinations which require all or more than one of the genes which indicates greater risk for ADHD. These arguments have been thoroughly reviewed. While the examiner maintains that each of the genes are distinct from each other and each of the combinations of genes are distinct from one another, solely to advance prosecution, the examiner has searched each of the recited genes and the combinations. However, this withdrawal of restriction for Group I, does not preclude the examiner from maintaining and deeming the restriction to a single gene or single combination of genes in other groups a burden.

Therefore, the restriction is made FINAL.

### **Response to Arguments**

The response has amended the claims to contain a distinct combination of genes which was not previously presented nor searched. Newly submitted claims 60-62 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons. The claims are now drawn to a distinct combination of genes which was not searched nor examined, the invention is distinct. The original claims examined were directed to at least one gene from TPH, PNMT, ADOA2A, NOS3 and NAT1. The claims now encompass ADRA2A, ADRA2C, NET, COMT, CHRNA both individually and in combination. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 60-62, in part, is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Furthermore, the response has cancelled Claim 9 and added New Claims 55-59, 64 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons. The claims are now drawn to generic method which was not searched nor examined, the invention is distinct. The original claims examined were directed to at least one gene from TPH, PNMT, ADOA2A, NOS3 and NAT1. The claims now are broadly drawn to any group of candidate genes. Moreover, the claims require distinct method steps from previously examined Claim 9. New Claim 55 also requires determining additive variance using multivariate regression analysis and backward elimination of non-significant candidate genes whereas Claim 9 requires no such analysis. Moreover, original Claim 9 required no assignment of gene score to

candidate genes depending on relative effects of the candidate gene genotype to phenotype. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 55-59, 63-64 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. Newly presented Claims 55-59, 63-64 are patentably distinct from Claims 60-62. The two groups are patentably distinct methods because they each have different objectives, different uses, different reagents and different method steps. The method of Claims 60-62 determine whether a subject is at risk for ADHD by determining the presence of SNP C108T RsaI at ADOA2A. Alternatively, the method of Claims 55-59, 63-64 is for determining whether genes contribute to ADHD by performing detailed statistical analysis for a combination of genes. Therefore the methods are distinct over one another. Therefore, claims 55-59, 63-64 are withdrawn from consideration as being directed to a non-elected invention.

### ***Priority***

5. This application claims priority to provisional application 60/195,312, filed April 10, 2000.

### ***Claim Rejections - 35 USC § 112- Enablement***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the

Art Unit: 1634

art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 60-62 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988). *Wands* states at page 1404,

"Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims."

The claims are broadly drawn to a method of determining a risk of an individual for attention deficit hyperactivity disorder (ADHD) by determining whether a subject has a non-wild-type allele from at least one gene selected from TPH, PNMT, ADOA2A, NOS3 and NAT1.

The specification teaches analyzing numerous genes for their association with ADHD. Figure 1 illustrates the ANOVA of ADHD scores for 40 genes. Figure 1A-2 teaches TPH SNP A779C has a p values of 0.495. Figure 1A-3 teaches PNMT GNP G-148A has a p value of 0.129. Figure 1B-2 teaches ADORA2A C108T (RsaI) has a p-value of 0.229. Figure 1B-2 teaches NOS3 has a p value of 0.830. Finally, Figure 1B-3

Art Unit: 1634

teaches NAT1 T1088 have a p value of 0.329. It is noted that none of these p-values are significant at  $\alpha = 0.05$ . Figure 2 appears to illustrate 22 genes when combined are associated with ADHD, however, it is unclear which 22 genes are involved in the analysis. Figure 3 appears to illustrate that each of TPH, PNMT, ADOA2A, NOS3 and NAT1 have a p values  $\leq 0.05$  for ADHD. Thus, there is apparent confusion between Figure 3 and Figure 1. The specification teaches there were 326 unrelated, non-Hispanic Caucasians. 271 of the subjects have Tourette syndrome and 55 were controls (page 9, lines 20-25). The text of the specification teaches ADOA2A was significant at  $p < 0.05$  (page 12, lines 15-18). Moreover, the specification teaches that "the only other new gene that produced a significant individual result was the NAT1 gene" (page 13, lines 10-11). With respect to NOS3, the specification teaches that NOS3 was significantly involved with all three traits" (page 15, lines 54-28).

The art teaches analysis of numerous genes in ADHD including ADOA2A, NAT1 and NOS3. Comings (Clin. Genet. Vol. 58, pages 31-40, July 2000) teaches each of these genes are not significantly associated with ADHD (Table 1). With respect to TPH, the art teaches there is a lack of association between the A218C polymorphism and ADHD in Chinese Han population. Tang (Am. J. of Med. Genetics, Vol. 105, pages 485-488, August 2001) teaches that the negative results of the study may be limited to the Chinese Han population or that the A218C polymorphism is not functionally significant and that some other variants are associated with ADHD (page 487, col 1-2).

The art also teaches that ADRA2A and ADRA2C genotypes are individually associated with ADHD (Comings et al. Clin. Genet. Vol. 55, pages 160-172, 1999, Table 2, page 165).

Moreover, Blum (US Pat. 6,132,724, October 2000) teaches association of CHRNA4 gene with ADHD (Example 28, col. 306). Similarly, Blum teaches the additive effect of three adrenergic genes (ADRA2A, ADRA2C, DBH) on ADHD subjects (Example 27, col. 294).

Neither the specification nor the art teach the skilled artisan how to use the invention as broadly as claimed. Based upon the teachings in the specification, it is unclear how to interpret the data. For example, the figures appear to illustrate that the genes are both significant and not significant. Therefore, it is unclear what is being shown in the figures and whether the genes are significant alone, i.e. not in combination with other genes. Moreover, it is unclear whether each of the combinations of gene are significantly associated with ADHD, or whether only the combination of 22 genes is significantly associated with ADHD.

Additionally, the claims are drawn to detecting a non-wild-type allele in the recited genes. The specification and the art have taught either a single SNP per gene or a couple of SNPs. The specification has not described which non-wild-type alleles are associated with ADHD and which alleles are neutral polymorphism. Numerous SNPs in the genome are known to be unassociated with diseases, especially with ADHD in particular. Therefore, the mere detection of a non-wild-type allele within TPH, PNMT, ADOA2A, NOS3 or NAT1 does provide indication that the subject is at an

increased risk for ADHD. The specification has examined SNP A779C within TPH gene; SNP G-148A within PNMT; SNP C108T (RsaI) within ADOA2A; and T1088A within NAT1. These specific mutations are not representative of all non-wild-type alleles within the genes. In order to practice the invention as broadly as claimed the skilled artisan would be required, unduly, to analyze the recited genes for alleles, determine whether they are wild-type or non-wild-type alleles and analyze the alleles for an association with ADHD. This trial and error experimentation is unpredictable. It is unpredictable whether the gene has alleles aside from the alleles studied in the instant application, whether these alleles are associated with ADHD, and whether the alleles confer an increased risk for ADHD or whether the alleles are protective and in fact are indicative of a decreased risk for ADHD. Moreover, the skilled artisan would be required to analyze numerous populations which are representative to determine whether the allele is associated with an increased risk over populations in general or whether the allele is associated within only certain populations. For example, in the instant case, in the event that the TPH gene A218C polymorphism is associated with non-Hispanic Caucasians, as asserted in the specification, the art teaches that there is no association in Chinese Han populations. Moreover, the specification teaches that there are differences in associations between various ethnic or racial backgrounds (page 7). The specification has only sampled unrelated non-Hispanic Caucasians. The specification has not provided a broad based population study which would be representative of numerous populations.

Therefore, based upon the analysis above, neither the specification nor the art teach the skilled artisan how to use the invention as broadly as claimed.

### **Response to Arguments**

The response traverses the rejection. The response asserts that polygenic disorders require analysis of multiple genes and are unlike single gene disorders which genes may not show significant correlation when analyzed individually (page 5-6 of Response filed December 23, 2002). This argument has been reviewed but is not convincing because the claims are drawn specifically to one or more genes. The claim therefore encompasses detection of a single gene. The elected ADORA2A gene is not associated at a significant level ( $p=0.229$ ) with ADHD (Figure 1b: sheet 4). Therefore, the claim is not enabled given the teachings in the art and the specification. Amendment of the claim to a specific combination of genes encompassing ADORA2A would be a separate consideration.

The response also provides clarification with respect to the figures which is greatly appreciated.

The response has cancelled Claim 9 in favor of Claims 55-59, 63-64. However, this amendment fails to overcome the identified problems. As discussed above, the method no longer falls within the scope of elected subject matter. Therefore, the claims have been withdrawn from consideration.

Thus for the reasons above and those already of record, the rejection is maintained.

**Conclusion**

**7. No claims allowable.**

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is (703) 306-5817. The examiner can normally be reached Monday-Friday from 8:00 a.m. to 5:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax number for this Group is (703) 305- 3014.

Any inquiry of formal matters can be directed to the patent analyst, Pauline Farrier, whose telephone number is (703) 305-3550.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
Jeanine Goldberg  
March 11, 2003

  
GARY BENZION, PH.D.  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600